Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Altman, Molly K ^a   Gopal, Vashisht ^b   Jia, Wei ^a   Yu, Shuangxing ^b   Hall, Hassan ^b   Mills, Gordon B ^b   McGinnis, A Cary ^a   Bartlett, Michael G ^a   Jiang, Guowei ^c   Madan, Damian ^d   Prestwich, Glenn D ^c   Xu, Yong ^c   Davies, Michael A ^b   Murph, Mandi M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d ECHELON BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOTAXIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; THIO CCPA 18:1; UNCLASSIFIED DRUG; ENPP2 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; MULTIENZYME COMPLEX; PHOSPHATIDIC ACID; PHOSPHODIESTERASE I; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MELANOMA; GENETIC TRANSFECTION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MULTIENZYME COMPLEXES; PHOSPHATIDIC ACIDS; PHOSPHODIESTERASE I; PYROPHOSPHATASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954312353     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-140     Document Type: Article

References (48)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012. 10.1056/NEJMra041245, 15342808.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
3. Weinberg RA. The Biology of Cancer. 2007, New York, NY: Garland Science, Taylor & Francis Group.
4. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47. 10.3322/canjclin.52.1.23, 11814064.
5. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007, 28:578-588. 10.1002/humu.20481, 17295241.
6. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992, 267:2524-2529.
7. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158:227-233. 10.1083/jcb.200204026, 2173129, 12119361.
8. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3:582-591. 10.1038/nrc1143, 12894246.
9. Murph M, Tanaka T, Liu S, Mills GB. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 2006, 12:6598-6602. 10.1158/1078-0432.CCR-06-1721, 17121877.
10. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 1996, 135:1071-1083. 10.1083/jcb.135.4.1071, 2133395, 8922387.
11. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 1998, 273:7906-7910. 10.1074/jbc.273.14.7906, 9525886.
12. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 1999, 274:27776-27785. 10.1074/jbc.274.39.27776, 10488122.
13. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003, 278:25600-25606. 10.1074/jbc.M302648200, 12724320.
14. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, Owman C, Sillard R, Leeb-Lundberg LM, Olde B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 2006, 318:619-628. 10.1124/jpet.105.098848, 16651401.
15. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006, 281:23589-23597. 10.1074/jbc.M603670200, 16774927.
16. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007, 363:861-866. 10.1016/j.bbrc.2007.09.063, 17905198.
17. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, Betz RC. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 2008, 40:329-334. 10.1038/ng.84, 18297070.
18. Murakami M, Shiraishi A, Tabata K, Fujita N. Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun 2008, 371:707-712. 10.1016/j.bbrc.2008.04.145, 18466763.
19. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003, 100:131-136. 10.1073/pnas.0135855100, 140905, 12502787.
20. Oyesanya RA, Greenbaum S, Dang D, Lee Z, Mukherjee A, Wu J, Dent P, Fang X. Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid. Mol Cancer 2010, 9:8. 10.1186/1476-4598-9-8, 2817642, 20074357.
21. Shah BH, Baukal AJ, Shah FB, Catt KJ. Mechanisms of extracellularly regulated kinases 1/2 activation in adrenal glomerulosa cells by lysophosphatidic acid and epidermal growth factor. Mol Endocrinol 2005, 19:2535-2548. 10.1210/me.2005-0082, 15928312.
22. Murakami-Murofushi K, Shioda M, Kaji K, Yoshida S, Murofushi H. Inhibition of eukaryotic DNA polymerase alpha with a novel lysophosphatidic acid (PHYLPA) isolated from myxoamoebae of Physarum polycephalum. J Biol Chem 1992, 267:21512-21517.
23. Mukai M, Iwasaki T, Tatsuta M, Togawa A, Nakamura H, Murakami-Murofushi K, Kobayashi S, Imamura F, Inoue M. Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion. Int J Oncol 2003, 22:1247-1256.
24. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, Murakami-Murofushi K, Koh E, Bandle RW, Byun HS, Bittman R, Fan D, Murph M, Mills GB, Tigyi G. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 2006, 281:22786-22793. 10.1074/jbc.M512486200, 16782709.
25. Uchiyama A, Mukai M, Fujiwara Y, Kobayashi S, Kawai N, Murofushi H, Inoue M, Enoki S, Tanaka Y, Niki T, Kobayashi T, Tigyi G, Murakami-Murofushi K. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta 2007, 1771:103-112.
26. Xu Y, Jiang G, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. J Med Chem 2006, 49:5309-5315. 10.1021/jm060351+, 16913720.
27. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 2008, 1781:588-594. 2597578, 18454946.
28. Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 2003, 278:11962-11969. 10.1074/jbc.M209168200, 12554733.
29. Hasegawa Y, Murph M, Shuangxing Y, Tigyi G, Mills GB. Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. Molecular Oncology 2008, 2:54-69. 10.1016/j.molonc.2008.03.009, 2597858, 19081821.
30. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008, 100:1630-1642. 10.1093/jnci/djn378, 2720766, 19001604.
31. Valentine WJ, Fujiwara Y, Tsukahara R, Tigyi G. Lysophospholipid signaling: beyond the EDGs. Biochim Biophys Acta 2008, 1780:597-605. 2751795, 17931789.
32. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003, 31:e154. 10.1093/nar/gng154, 291882, 14654707.
33. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008, 1:13. 10.1186/1755-8794-1-13, 2408576, 18442402.
34. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Borresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 2009, 4:e5583. 10.1371/journal.pone.0005583, 2679144, 19440550.
35. Ferguson CG, Bigman CS, Richardson RD, van Meeteren LA, Moolenaar WH, Prestwich GD. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 2006, 8:2023-2026. 10.1021/ol060414i, 2528860, 16671772.
36. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006, 281:17492-17500. 10.1074/jbc.M601803200, 16627485.
37. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007, 9:1-18. 10.1017/S1462399407000476, 17935635.
38. Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991, 51:4549-4556.
39. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, Tigyi G, Prestwich GD. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2007, 2:679-690. 10.1002/cmdc.200600280, 17443831.
40. Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther 2008, 7:3352-3362. 10.1158/1535-7163.MCT-08-0463, 18852138.
41. Samadi N, Gaetano C, Goping IS, Brindley DN. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009, 28:1028-1039. 10.1038/onc.2008.442, 19079345.
42. Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, Higashi K, Yokota H, Okudaira S, Kishimoto T, Watanabe T, Koike Y, Ikeda H, Kozai Y, Kurokawa M, Aoki J, Yatomi Y. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 2008, 143:60-70. 10.1111/j.1365-2141.2008.07325.x, 18710386.
43. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T, Yanase M, Tejima K, Nishikawa T, Arai M, Arai H, Omata M, Fujiwara K, Yatomi Y. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007, 41:616-623. 10.1097/01.mcg.0000225642.90898.0e, 17577119.
44. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Kennedy G, Arai H, Aoki J, Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005, 435:104-108. 10.1038/nature03505, 1369590, 15875025.
45. Wei Q, St Clair JB, Fu T, Stratton P, Nieman LK. Reduced expression of biomarkers associated with the implantation window in women with endometriosis. Fertil Steril 2009, 91:1686-1691. 10.1016/j.fertnstert.2008.02.121, 2697117, 18672236.
46. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67. 10.1038/nrd3010, 20043028.
47. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004, 279:17634-17639. 10.1074/jbc.M313927200, 14744855.
48. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK, Fang X. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008, 19:5435-5445. 10.1091/mbc.E08-03-0316, 2592656, 18843048.